Identification of markers in lung and breast cancer
OwnerTony Godfrey, Liqiang Xi +2inventors
InventorsTony Godfrey, Liqiang Xi, Siva Raja, William Gooding
Life of this patent
Estimating the term…
Abstract
Methods for identifying expression of markers indicative of the presence of breast cancer and lung cancer are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods.
Claims60
A method of identifying expression of markers indicative of the presence of breast cancer cells in a lymph node of a patient, comprising determining if:
- (a) a first mRNA species specific to TACSTD1 is overabundant in an RNA sample prepared from the lymph node;
- (b) a first mRNA species specific to CK19 and a second mRNA species specific to one of PIP and MGB1 are overabundant in an RNA sample prepared from the lymph node;
- or
- (c) a first mRNA species specific to CK7 and a second mRNA species specific to one of PIP, MGB1 and MGB2 are overabundant in an RNA sample prepared from the lymph node,
- the overabundance of the mRNA species being indicative of the presence of displaced breast cells in the lymph node.
A method of identifying expression of markers indicative of the presence of lung cancer cells in a lymph node of a patient, comprising determining if a first mRNA species specific to one of CK7, CK19, PVA, SCCA1.2, SFTPB and TACSTD1 is overabundant in an RNA sample prepared from the lymph node, the overabundance of the mRNA species being indicative of the presence of displaced lung cells in the lymph node.
An article of manufacture comprising packaging material and:
- (a) one or more nucleic acids specific to one or more of CEA, CK19, MGB1, MGB2, PIP and TACSTD1, wherein the packaging material comprises an indicia indicating that the one or more nucleic acids can be used in a method of identifying expression of markers indicative of the presence of breast cancer cells in a lymph node of a patient;
- or
- (b) one or more nucleic acids specific to one or more of CEA, CK7, CK19, PVA, SCCA1.2, SFTPB and TACSTD1, wherein the packaging material comprises an indicia indicating that the one or more nucleic acids can be used in a method of identifying expression of markers indicative of the presence of lung cancer cells in a lymph node of a patient.
A composition comprising:
- (a) one or more primers or probes specific to one or more of CEA, CK19, MGB1, MGB2, PIP and TACSTD1 and RNA extracted from a lymph node of a patient diagnosed with or suspected of having breast cancer;
- or
- (b) one or more primers or probes specific to one or more of CEA, CK7, CK19, PVA, SCCA1.2, SFTPB and TACSTD1 and RNA extracted from a lymph node of a patient diagnosed with or suspected of having lung cancer.
Dependencies are inferred from the claim text.